Summary of Amgen's Conference Call Company Overview - **Company**: Amgen - **Event**: 46th Annual TD Cowen Healthcare Conference - **Key Participants**: Justin Claeys (SVP of Finance), Kave Niksefat (SVP of Global Marketing and Access), Casey Capparelli (Head of IR) Core Industry Insights Financial Performance - Amgen exited 2025 with strong momentum, with 13 products delivering double-digit growth and 14 products exceeding $1 billion in annual sales [2][10] - The company reported double-digit growth in both revenue and earnings per share for 2025, supported by six key growth drivers: Repatha, EVENITY, TEZSPIRE, rare disease portfolio, innovative oncology, and biosimilars [2][10] Product Performance - **Repatha, EVENITY, TEZSPIRE**: Each grew over 30% year-over-year in 2025, representing multi-billion dollar global franchises [2] - **Rare Disease Portfolio**: Generated $5 billion in sales for 2025, up 14% year-over-year, driven by new patient reach and geographic expansion [3] - **Uplizna**: Grew 73% in 2025, with expectations for continued growth following recent approvals [3] - **Biosimilars Portfolio**: Generated $3 billion in sales, growing 37% year-over-year, with strong uptake of PAVBLU [4] Pipeline Developments - 2026 is expected to be a disciplined data year with multiple phase 2 and phase 3 programs [5] - **MariTide**: Positioned as a differentiated treatment for obesity and Type 2 diabetes, with a unique dosing schedule [5] - **Olpasiran**: A small interfering RNA medicine targeting Lp(a), with ongoing studies [6] - **Dazodalibep**: Targeting Sjögren's disease, with two phase III studies expected to complete in the second half of 2026 [6] Market Dynamics Competitive Landscape - Increased competition in the cardiometabolic market, with new entrants expected to grow overall market penetration rather than just share [20] - Amgen's Repatha has a competitive edge due to extensive clinical data, including unique primary prevention data [21] Access and Pricing Strategies - Amgen has successfully negotiated access across various therapeutic areas, ensuring affordability and accessibility of its medicines [12] - **AmgenNow**: A direct-to-patient program for Repatha priced at $239 per month, aimed at uninsured or high-deductible patients [17][18] - The average copay for Repatha has decreased to less than $50 a month, with over half of Medicare patients no longer requiring prior authorization [16] Challenges - Otezla faces European generic competition, with sales of $282 million in 2025 and expected erosion in 2026 due to biosimilar competition [9] - The first quarter of the year typically sees lower sales due to seasonal headwinds and inventory build from the previous quarter [8][9] Additional Insights - The company is focusing on expanding its market share in severe asthma with TEZSPIRE, which can be used across different patient phenotypes [22][24] - Uplizna is being utilized across all lines of therapy, with a significant portion of prescriptions coming from bio-naive patients [28] - The European market remains challenging, but there are signs of governments beginning to react positively to drug pricing and access [33] Conclusion Amgen is well-positioned for sustained long-term growth with a diversified portfolio and a robust pipeline. The company is navigating competitive pressures while focusing on access and affordability for its products, particularly in the cardiometabolic and rare disease markets.

Core Insights - Royalty Pharma experienced a "landmark year" in 2025, achieving double-digit growth in both portfolio and royalty receipts, and internalizing its external manager to enhance governance and reduce costs [2][5][18] Financial Performance - The company reported a return on invested capital (ROIC) of 15.8% and return on equity (ROE) of 22.8% for 2025 [5] - Royalty receipts grew by 13% for the year and 17% in the fourth quarter, while portfolio receipts increased by 16% for the year and 18% in the fourth quarter [13] - The company ended 2025 with $619 million in cash, $9.2 billion in debt, and a leverage ratio of approximately 3x [3][15] Cost Management - Management expects to achieve $100 million in cost savings in 2026 due to the internalization of the external manager, aiming for an operating and professional cost ratio of 4%–5% over time [1][5] Strategic Transactions - In 2025, Royalty Pharma executed eight transactions with a total announced value of $4.7 billion, deploying $2.6 billion, marking its strongest year for synthetic royalties [4][6][7] - The company reviewed over 480 potential royalty transactions, resulting in 109 in-depth reviews and 35 proposals [6] 2026 Guidance - For 2026, management guided portfolio receipts of $3.275 billion to $3.425 billion, implying a royalty growth of approximately 3% to 8% [3][16] - The guidance reflects anticipated headwinds from product loss of exclusivity and the introduction of biosimilars [2][16] Pipeline and Future Catalysts - The company estimates combined peak sales of over $43 billion across 20 development-stage therapies, translating to more than $2.1 billion in peak annual royalties [11] - Upcoming pivotal readouts are expected over the next 24 months, including data from Revolution Medicines and Novartis [17] Capital Allocation - Royalty Pharma returned $1.7 billion to shareholders in 2025 through $1.2 billion in buybacks and over $500 million in dividends [14]

Group 1 - UBS upgraded its rating for Amgen (AMGN.US) from "Neutral" to "Buy," raising the target price from $317 to $380, citing two late-stage products, MariTide and olpasiran, as key growth drivers until 2030 [1] - The target price represents nearly a 15% upside from Amgen's closing price on Tuesday [1] - MariTide (AMG 133) is a GLP-1R agonist/GIPR antagonist for treating obesity and type 2 diabetes, showing an average weight loss of 20% in obese/overweight patients without type 2 diabetes after 52 weeks, with no plateau in weight loss [1] Group 2 - Olpasiran (AMG 890) is an investigational siRNA therapy targeting the mRNA of the Lp(a) gene to reduce Lp(a) production, a genetically determined independent risk factor for cardiovascular disease [1] - Patients receiving 75mg or higher doses of olpasiran showed a reduction of Lp(a) by 95% or more at week 36 compared to the placebo group, with over 98% of patients achieving Lp(a) levels of 125nmol/L or lower [1] - UBS analysts noted that MariTide's potential for monthly dosing could enhance patient compliance, despite concerns about tolerability in trial results [2]

Summary of Royalty Pharma Conference Call Company Overview - Royalty Pharma is one of the largest funders of life sciences globally and the largest in royalty-based funding, with over 25 years of experience [4][6] - The company went public in 2020 and currently generates over $3 billion in revenue [6][8] - Royalty Pharma owns royalties on approximately 40-45 products, with a business model focused on capital deployment and shareholder returns [7][8] Key Portfolio Assets - Recent investment includes a $250 million R&D funding deal with Biogen for a lupus drug, litafilimab, which is in phase three trials [18][19] - The lupus market is seen as under-penetrated, with significant growth potential anticipated [20][22] - Other notable investments include royalties from MorphoSys and products in the inflammatory bowel disease (IBD) space [26][28] Investment Strategy - The company emphasizes investing in products that are meaningful to patients rather than solely focusing on attractive returns [11][12] - A rigorous vetting process is employed to assess potential investments, involving a deep diligence process [10][11] - Royalty Pharma has developed a synthetic royalty model to provide funding against specific drugs or R&D programs, filling a gap in the funding landscape [15][16] Market Dynamics - The company views its business as having a countercyclical nature to the biopharma funding environment, with a consistent need for capital in the industry [14][15] - The funding environment is currently challenging, but Royalty Pharma has successfully deployed capital into promising products [16] Recent Developments - The company has internalized its management structure, aligning the interests of the team with shareholders [42][46] - A $3 billion buyback program was announced, reflecting a commitment to shareholder value [46][47] - Guidance for portfolio receipts was raised due to favorable foreign exchange rates and growth in existing royalties [48][49] Diligence and Data Analytics - Royalty Pharma has invested significantly in its diligence platform, employing a generalist approach to evaluate various therapeutic areas [54][55] - The company utilizes extensive data sources and real-world evidence to conduct deep market evaluations [55][57] Conclusion - Royalty Pharma is positioned as a key player in the biopharma funding landscape, with a strong focus on meaningful product investments and a robust diligence process. The company is optimistic about future growth opportunities in various therapeutic areas, particularly lupus and cardiovascular diseases [20][34][46]

Summary of Royalty Pharma Conference Call Company Overview - **Company**: Royalty Pharma - **Key Executives**: Terence Coyne (Executive VP and CFO), Marshall Uerst (EVP, Head of Research and Investments) Key Industry Insights - **Therapeutics Landscape**: The current environment in the biopharma market is characterized by uncertainty, but Royalty Pharma remains optimistic about finding attractive royalty opportunities amidst this turmoil [2][6][10] - **Capital Allocation**: The company has a balanced approach to capital allocation, focusing on share buybacks and business development (BD) to maximize returns [3][7][25] Financial Performance - **Q1 Performance**: Royalty Pharma reported a 17% growth in top-line revenue and a 12% increase in royalty receipts, maintaining consistent growth since its IPO [4][6] - **Share Buybacks**: Approximately $725 million worth of shares were repurchased in Q1, indicating a strong commitment to returning value to shareholders [7] Strategic Focus - **Internalization Transaction**: The internalization transaction was approved by 89.9% of shareholders, which is seen as a positive development for the company [2] - **Deal Pipeline**: The company is actively seeking new royalty deals, leveraging its flexibility to adapt to changing market conditions [10][11] - **Regulatory Environment**: Royalty Pharma is cautious but optimistic about drug approvals, believing that strong data will lead to successful outcomes regardless of regulatory changes [22][23] Market Risks and Opportunities - **Tariffs and Drug Pricing**: The company does not foresee significant exposure to tariffs due to its business model, which typically avoids tariff-bearing sales [15][18] - **FDA Dynamics**: The company believes that drugs with strong clinical data will continue to receive approvals, despite potential regulatory challenges [22] - **Royalty Market Growth**: The royalty market is expanding, with increasing opportunities for funding in the biopharma ecosystem [41][44] Portfolio Highlights - **Vertex Royalty**: The early adoption of Vertex's triplet product is gradual, but Royalty Pharma remains confident in its long-term value [33][34] - **Tourette's Asset**: The company identified a significant market opportunity in Tourette's syndrome, with over 100,000 patients and no new drugs approved in over a decade [47][48] - **Cytokinetics Partnership**: The long-term view on investments allows Royalty Pharma to remain optimistic about partnerships, even amidst short-term challenges [53][54] - **Olanzapine LAI**: The company is excited about the potential of the olanzapine long-acting injection, addressing a significant unmet need in the market [66][68] Conclusion - Royalty Pharma is well-capitalized with over $1 billion in cash and a debt-to-EBITDA ratio of 3x, allowing for flexibility in pursuing new deals or share buybacks [26][28] - The company maintains a positive outlook on the royalty market and is strategically positioned to capitalize on emerging opportunities while managing risks effectively [41][44]